针对IRE1的基于结构的药物设计:用于治疗癌症的基方法
Alireza Poustforoosh1, Sanaz Faramarz2, Mohammad Hadi Nematollahi2,3
1Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Drug research
|December 22, 2023
概括
新设计的针对因诺醇需要酶1 (IRE1) 的化合物显示出对癌症治疗的前途. 化合物17通过形成共价键,有效地抑制IRE1,这表明了新的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 细胞内膜网膜 (ER) 的压力和未折叠的蛋白质反应 (UPR) 与癌症进展有关.
- 需要内醇的酶1 (IRE1) 是ER压力的关键传感器,具有前瘤作用.
- 准IRE1活性位点为癌症治疗提供了一种治疗策略.
研究的目的:
- 设计使用4μ8C结构作为模板的新型IRE1抑制剂.
- 评估新设计的化合物的结合亲和力和类似药物的特性.
主要方法:
- 进行了共价分子对接研究,以评估结合亲和力.
- 功能组被添加到4μ8C支架上.
- 用ADMET分析来预测体外和体内潜力.
主要成果:
- 将基组添加到4μ8C中,提高了结合亲和力.
- 化合物17与Lys907.7形成了强大的共价键.
- 对ADMET的分析表明,化合物17具有类似药物的特性.
结论:
- 设计化合物17有效抑制IRE1活动.
- 这种化合物代表了癌症治疗的有希望的治疗候选者.
- 需要进一步进行体外和体内研究.
更多相关视频
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.2K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
相关概念视频
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
